Non-Control/Non-Affiliate Investments are investments that are neither Control Investments nor Affiliate Investments. Control Investments generally are defined by the Investment Company Act as investments in companies in which the Company owns more than 25% of the voting securities and/or has the power to exercise control over the management or policies of the company. Affiliate Investments generally are defined by the Investment Company Act as investments in companies in which the Company owns between 5% and 25% of the voting securities.

[2]

As defined in the Investment Company Act, the Company is deemed to be both an "Affiliated Person" of and to "Control" these portfolio companies as the Company owns more than 25% of the portfolio company's outstanding voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). See Schedule 12-14 in the accompanying notes to the Consolidated Financial Statements for transactions during the nine months ended June 30, 2026 in which the issuer was both an Affiliated Person and a portfolio company that the Company is deemed to control.

[3]

Control Investments generally are defined by the Investment Company Act, as investments in companies in which the Company owns more than 25% of the voting securities or maintains greater than 50% of the board representation.

[4]

As of September 30, 2025, these investments are categorized as Level 3 within the fair value hierarchy established by ASC 820 and were valued using significant unobservable inputs.

[5]

Investment has undrawn commitments. Unamortized fees are classified as unearned income which reduces cost basis, which may result in a negative cost basis. A negative fair value may result from the unfunded commitment being valued below par.

[6]

Investment is not a qualifying asset as defined under Section 55(a) of the Investment Company Act. Under the Investment Company Act, the Company may not acquire any non-qualifying asset unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company’s total assets. As of June 30, 2026, qualifying assets represented 73.8% of the Company’s total assets and non-qualifying assets represented 26.2% of the Company’s total assets.

[7]

Non-Control/Non-Affiliate Investments are investments that are neither Control Investments nor Affiliate Investments. Control Investments generally are defined by the Investment Company Act of 1940, as amended (the “Investment Company Act”), as investments in companies in which the Company owns more than 25% of the voting securities and/or has the power to exercise control over the management or policies of the company. Affiliate Investments generally are defined by the Investment Company Act as investments in companies in which the Company owns between 5% and 25% of the voting securities.

[8]

The interest rate on the principal balance outstanding for most floating rate loans is indexed to the secured overnight financing rate (“SOFR”), the euro interbank offered rate (“EURIBOR” or “E”), the sterling overnight index average (“SONIA”), the Tokyo overnight average rate ("TONA"), the Canadian overnight repo rate average ("CORRA"), the bank bill swap rate ("BBSW"), the Norwegian interbank offered rate (“NIBOR”), the Stockholm interbank offered rate ("STIBOR"), and/or an alternate base rate (e.g., prime rate), which typically resets semi-annually, quarterly, or monthly at the borrower’s option. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rate or the alternate base rate based on each respective credit agreement and the cash interest rate as of period end. As of June 30, 2026, the reference rates for the Company’s variable rate loans were the 30-day SOFR at 3.63%, the 90-day SOFR at 3.63%, the 180-day SOFR at 3.67%, the PRIME at 6.75%, the SONIA at 3.75%, the TONA at 0.98%, the 30-day CORRA at 2.28%, the 90-day BBSW at 4.46%, the 90-day NIBOR at 4.56%, the 180-day STIBOR at 2.12%, the 30-day EURIBOR at 2.20%, the 90-day EURIBOR at 2.32% and the 180-day EURIBOR at 2.57%. Most loans include an interest floor, which generally ranges from 0% to 3.00%. SOFR and SONIA based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread.

[9]

Investment is not a qualifying asset as defined under Section 55(a) of the Investment Company Act. Under the Investment Company Act, the Company may not acquire any non-qualifying asset unless, at the time the acquisition is made, qualifying assets represent at least 70% of the Company’s total assets. As of September 30, 2025, qualifying assets represented 72.1% of the Company’s total assets and non-qualifying assets represented 27.9% of the Company’s total assets.

[10]

The interest rate on the principal balance outstanding for most floating rate loans is indexed to SOFR, EURIBOR, SONIA, TONA, CORRA, BBSW, NIBOR, STIBOR, and/or an alternate base rate (e.g., prime rate), which typically resets semi-annually, quarterly, or monthly at the borrower’s option. The borrower may also elect to have multiple interest reset periods for each loan. For each of these loans, the Company has provided the applicable margin over the reference rate or the alternate base rate based on each respective credit agreement and the cash interest rate as of period end. As of September 30, 2025, the reference rates for the Company’s variable rate loans were the 30-day SOFR at 4.13%, the 90-day SOFR at 3.98%, the 180-day SOFR at 3.85%, the PRIME at 7.25%, the SONIA at 4.19%, the TONA at 0.75%, the 90-day CORRA at 2.54%, the 90-day BBSW at 3.58%, the 90-day NIBOR at 4.13%, the 90-day STIBOR at 1.89%, the 30-day EURIBOR at 1.93%, the 90-day EURIBOR at 2.03% and the 180-day EURIBOR at 2.10%. Most loans include an interest floor, which generally ranges from 0% to 3.00%. SOFR and SONIA based contracts may include a credit spread adjustment that is charged in addition to the base rate and the stated spread.

[11]

As of June 30, 2026, these investments are categorized as Level 3 within the fair value hierarchy established by Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 820, Fair Value Measurements and Disclosures (“ASC 820”) and were valued using significant unobservable inputs.

[12]

[13]

This investment represents a credit default swap that functions, in substance, like a credit linked note and represents a credit risk transfer for a pool of reference assets owned by a bank. The Company fully funded margin up front and in return the Company receives periodic interest payments. The Company’s risk of loss is limited to the principal amount disclosed herein. The reference assets are primarily composed of investment grade corporate debt. The Company may be exposed to counterparty risk, which could make it difficult for the Company to collect on obligations, thereby resulting in potentially significant losses. In addition, the Company only has a contractual relationship with the bank, and not with the reference obligors of the reference assets. Accordingly, the Company generally may have no right to directly enforce compliance by the reference obligors with the terms of the reference assets. The Company will not directly benefit from the reference assets and will not have the benefit of the remedies that would normally be available to a holder of such reference assets. In addition, in the event of the insolvency of the counterparty, the Company may be treated as a general creditor of such counterparty, and will not have any claim with respect to the reference assets.

(13)Income producing through payment of dividends or distributions.

(14)Security acquired in transaction exempt from registration under the Securities Act of 1933, as amended (the "Securities Act"), and may be deemed to be “restricted security” under the Securities Act. As of June 30, 2026, the aggregate fair value of these securities is $35,111, or 0.8% of the Company’s net assets. The acquisition dates of the restricted securities are as follows:

Portfolio Company

Type of Investment

Acquisition Date

ADC Therapeutics SA

Warrants

8/15/2022

AIP RD Buyer Corp.

Common Stock

12/23/2021

athenahealth Group Inc.

Preferred Equity

2/15/2022

BioXcel Therapeutics, Inc.

Common Stock

11/25/2024

BioXcel Therapeutics, Inc.

Warrants

4/28/2022

BioXcel Therapeutics, Inc.

Warrants

3/20/2024

Delta Leasing SPV II LLC

Preferred Equity

8/31/2022

Delta Leasing SPV II LLC

Common Stock

8/31/2022

Delta Leasing SPV II LLC

Warrants

8/31/2022

Eyesouth Eye Care Holdco LLC

Common Stock

10/7/2022

IDF 14 FinanceCo, LLC

Warrants

6/24/2026

JN Bidco LLC

Common Stock

8/12/2024

Mesoblast, Inc.

Warrants

12/20/2021

Paulus Holdings Public Limited Company

Preferred Equity

10/14/2022

Paulus Holdings Public Limited Company

Warrants

10/14/2022

PetVet Care Centers, LLC

Preferred Equity

11/14/2023

Pluralsight, LLC

Common Stock

8/22/2024

Seres Therapeutics, Inc.

Warrants

4/27/2023

OSCF EDL JV, LLC

Membership Interest

6/26/2026

[14]

Security acquired in transaction exempt from registration under the Securities Act and may be deemed to be “restricted security” under the Securities Act. As of September 30, 2025, the aggregate fair value of these securities is $31,652, or 0.7% of the Company’s net assets. The acquisition dates of the restricted securities are as follows:

Portfolio Company

Type of Investment

Acquisition Date

ADC Therapeutics SA

Warrants

8/15/2022

AIP RD Buyer Corp.

Common Stock

12/23/2021

athenahealth Group Inc.

Preferred Equity

2/15/2022

BioXcel Therapeutics, Inc.

Common Stock

11/25/2024

BioXcel Therapeutics, Inc.

Warrants

4/28/2022

BioXcel Therapeutics, Inc.

Warrants

3/20/2024

Delta Leasing SPV II LLC

Preferred Equity

8/31/2022

Delta Leasing SPV II LLC

Common Stock

8/31/2022

Delta Leasing SPV II LLC

Warrants

8/31/2022

Eyesouth Eye Care Holdco LLC

Common Stock

10/7/2022

JN Bidco LLC

Common Stock

8/12/2024

Mesoblast, Inc.

Warrants

12/20/2021

Paulus Holdings Public Limited Company

Preferred Equity

10/14/2022

Paulus Holdings Public Limited Company

Warrants

10/14/2022

PetVet Care Centers, LLC

Preferred Equity

11/14/2023

Pluralsight, LLC

Common Stock

8/22/2024

Seres Therapeutics, Inc.

Warrants

4/27/2023

[15]

This investment was on non-accrual status as of September 30, 2025.

[16]

In addition to the interest earned based on the stated interest rate of this investment, which is the amount reflected in this schedule, the Company may be entitled to receive additional interest as a result of an arrangement with other lenders to the extent an investment has been allocated to “first out” and “last out” tranches, whereby the “first out” tranche will have priority as to the “last out” tranche with respect to payments of principal, interest and any amounts due thereunder and the Company holds the “last out” tranche.

[17]

This investment was valued using net asset value as a practical expedient for fair value consistent with ASC 820. These investments are excluded from the hierarchical levels.

[18]

This investment was on non-accrual status as of June 30, 2026.

[19]

This investment was on non-accrual status as of June 30, 2026.

[20]

[21]

Income producing through payment of dividends or distributions.

[22]

Income producing through payment of dividends or distributions.